Significant advancements will bring curative therapies to many individuals suffering from rare hereditary diseases. Supplemental indications on existing specialty therapies has led to an increase in use, as well as an aging population of baby boomers contributing to the increased use or volume of specialty drugs being prescribed. Specialty and high-cost medications continue to dominate the news. It is the highest cost gene therapy, currently at $2M per patient, and total sales of $361M in 2019. By focusing on total health, not just prescriptions, we’re thinking bigger. There is a $62B market for biosimilars over the next four years as competition in the specialty drug market increases. Unique Reimbursement Models for High Investment Therapy. IQVIA website. Stanton D. In the pipeline: Surge of cell and gene therapies likely in 2020. Progress has been exceptional but these high investment therapies have also introduced new challenges for employers and the payer community.4The 1983 Orphan Drug Act was enacted to incentivize research for rare diseases which are estimated to afflict 10% of Americans. Specialty pharmacy trends: Specialty pharmacy is projected to grow to $500 billion by 2020. Specialty medication is expected to increase to 50% of drug costs by 2020. High investment therapies have stretched current reimbursement models beyond their capacity. Accredited residency programs meet specific standards and guidelines. Increasingly blurred lines between care settings. Genetic information is gathered through genome sequencing where researchers are able to identify specific abnormalities and come up with drugs and therapies targeted towards them. FAQs from Genetic and Rare Disease Information Center, U.S. Department of Health and Human Services During the early 1990’s there were fewer than 30 specialty medications approved by the FDA. (See Exhibit 51 in our new report.) Spark agreed to the same terms for Luxterna to treat a retinal disease causing blindness. /publications/specialty-pharmacy-times/2020/February2020/editors-note-top-trends-for-2020-in-specialty-pharmacy, Copyright Specialty Pharmacy Times 2006-2019, 2 Clarke Drive Suite 100 Cranbury, NJ 08512 P:609-716-7777 F:609-716-9038, https://www.iqvia.com/en/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023, https://payorsolutions.cvshealth.com/insights/pipeline-preview-2020. Marc Stranz, PharmD, and Justin Linhorst, MBA. It is a pre-exposure prophylaxis for HIV and will have the potential to impact nearly $3B in annual sales. We’re the pharmacy benefits manager behind Anthem, Inc., so finding new ways to help customers and their members is second nature. Our specialty pharmacy readers are amongst the most informed in health care. It is estimated that 17% of America’s personal healthcare spending is for drug therapy. While initially often opened independently, many specialty pharmacies have been acquired by traditional chain pharmacies and investment firms in recent years. Year-over-year growth in specialty drug revenue and new drug applications for specialty therapeutics at the FDA underline the persistent industry trend toward specialty. It’s no secret that technology is constantly evolving within the health care landscape, in which harnessing the power of data and automatization can spur significant progress in patient care, reimbursement, and overall efficiency. We have reorganized or moved some sections, but there are no changes to your plan besides the changes listed below. IQVIA Institute. Insight provided by Bryan Klazinga, VP of Pharmacy Benefits. Top therapy areas, which contributed to trend, are autoimmune/anti-inflammatory drugs, along with cancer drugs for lung and breast cancer, due to increased costs over older treatments and brand inflation. Volume Based Purchasing – the Netflix Model. Healthcare will be a … The lines between care settings … Zolgensma, (Novartis), approved to treat a rare spinal defect, is the highest cost gene therapy currently at $2M per patient. Collaboration between payers, providers and manufacturers is possible, and most likely the best strategy to ensure cost effective access to quality care. In 2020, specialty pharmacies must embrace initiatives to quantify improved clinical outcomes, lower costs, and create more value for all stakeholders to obtain maximum compensation for their services. Those 2 products are likely to be joined by a third CAR T-cell therapy for lymphoma: Celgene’s lisocabtagene maraleucel (liso-cel) for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and follicular lymphoma. Value based arrangements and risk sharing across plan sponsors, PBMs, Payers and manufacturers is being considered in order to sustain affordability, ensure access to care and continue to incentivize manufacturer research and development efforts. State of Louisiana’s contract with Asegua/Gilead allows unrestricted access of the drug Epclusa, to treat and cure Hepatitis-C, for their entire Medicaid and prison population. More than 900 investigational new drug applications have been submitted to the FDA in 2020. This product if approved will be an oral agent and a likely specialty pharmacy play. Puts the onus on the Payer to prove failure of efficacy. Key Trends in US Specialty Pharmacy Payer Perspectives and Developer Strategies, 2020-23 CERTARA TRENDS BRIEF. Specialty drugs currently represent just under 2% of the prescriptions, but nearly 40% of spending in the same channels. Specialty products and services were considered the most profitable among all the pharmacy trends for this year, and 2020 will see a bigger market for these medications as they become part of the top pharmacy trends for 2020. Several trends will further address the need to change the way we deliver and pay for healthcare in the U.S. have been made to your 2020 … If all goes well, 2021 will begin our return to normalcy, as vaccines roll out across the country. There are dozens of gene therapy products on the near horizon. Increasing complexity and growth in integrated delivery networks. These therapies offer immense potential benefits to patients—in some cases offering cures to life-threatening diseases in a single dose. 2020 Trends in Pharmacy Care: Technology. See below a snapshot of specialt… Specialty Pharmacy Trends for 2020 and Beyond. Specialty drugs are expected to represent almost 50 percent of total prescription drug spending in 2020. Sales of Zolgensma totaled $361M in 2019. Denise CabreraLicensed Clinical PharmacistNational Pharmacy Practice Leader   McGriff Employee Benefit Solutions813-682-1515Denise.Cabrera@mcgriffinsurance.com, Specialty Pharmacy Trends for 2020 and Beyond, Register: Online HRCI | PHR | SPHR Certification Exam Prep Class, https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NHE-Fact-Sheet, https://bioprocessintl.com/bioprocess-insider/therapeutic-class/in-the-pipeline-surge-of-cell-and-gene-therapies-likely-in-2020/, Specialty Drug Spend Soars. These high investment therapies have stretched current reimbursement models beyond their capacity. [4] The Evolution of Specialty Pharmacy Today, this number has increased to over 400. You can watch the full video below. 2019. Novartis expects to treat 100 infants each quarter. I review: Health plan sponsors are rightly concerned about the possibility that their medical costs could skyrocket if a few of their members started treatment. During 2020, the COVID-19 pandemic disrupted every aspect of the pharmaceutical channel—and our lives. Accreditation is granted by ASHP in partnership with AMCP under the Required Competency Areas, Goals, and Objectives for PGY1 Managed Care Pharmacy Residencies.. Find an Accredited Residency 2020-06-18 19:11:00. Pharmacy and healthcare provider markets experienced unprecedented volatility. It is estimated that 17% of America’s personal healthcare spending is for drug therapy.1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. Gene therapy is designed to correct inherited genetic defects therefore it is curative and preventative for future generations.The FDA has approved 4 gene therapies to date, including Zolgensma (Novartis), approved to treat a rare spinal defect. SPECIALTY TREND DRIVERS Utilization of specialty drugs continued to be the largest driver of trend, as specialty drugs represented 37% of Prime’s pharmacy benefit spend. There are a couple of products aimed at building up a level of tolerance, which can help prevent a fatal allergic reaction due to accidental exposure. Medical Pharmacy Trend Report For 10 years, the Magellan Rx Management Medical Pharmacy Trend Report has unlocked pharmacy trend updates and emerging strategies to manage rising specialty spend on the medical benefit. Chaguturu S. Pipeline Preview 2020. Specialty Biosimilar Pipeline $62 Billion Biosimilar Market 2020 – 2024. Trends in FDA approval of Specialty Drugs 1990 through 2017, RJ Health, 2018. 1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. Expect these therapies to be hyper expensive and create a new set of challenges of payers and manufacturers. Can Formulary Management Bring It Down to Earth?, Managed Care, 2019, FAQs About Rare Diseases, Genetic and Rare Diseases Information Center, U.S. Department of Health and Human Services, 2017, https://www.cigna.com/newsroom/news-releases/2019/pdf/cigna-health-services-business-pioneers-an-innovative-solution-to-affordably-bring-life-changing-therapies-to-patients.pdf, http://image.messageinsite.com/lib/fe5615707d600c747210/m/2/757027d4-dff0-4c1b-a50a-ce78326b9917.pdf, 5 Ways Talking to Strangers May Boost Your Emotional Intelligence, Driving Optimal Results Through Individual/Team Performance-Based Incentive Compensation Plans, The Future of Benefits Administration Technology for HR Professionals, Most Brokers Say They Have All the Answers, Is Western Governors University Accredited | Read the Latest World News - News World, The Three Top Challenges to Earning a Degree, Factors in Assessing Your Hiring Strategy - HRProfessionalsMagazine, Recruiting Tips During Times of Uncertainty, Profile: Emily M. Dickens, SHRM Corporate Secretary and Chief of Staff, Preview of SHRM-Atlanta SOAHR Conference March 25-27. As we enter a new decade, the healthcare industry will continue to address challenges like reimbursement for high investment therapies and the impact of social determinants of health. There have been 2 chimeric antigen receptor (CAR-T) approvals for certain kinds of non-Hodgkin lymphoma: Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel). The biosimilar for Truvada is expected to launch in 2021. changes . These lifesaving products work by removing T-cells from the patient and genetically re-engineer those cells to target a specific cancer cell as diagnosed by the patient’s health care team. As specialty drugs have gained a stronger foothold in the United States, the creation and utilization of specialty pharmacies has also expanded. And that’s how we’ll change pharmacy benefits for the better. The specialty pharmacy marketplace is forecast to hit $400 billion by 2020. Specialty pharmacies are designed specifically to manage the necessary handling, storage, and distribution of complex therapy drugs that require high-touch patient management. They have tripled as a share of accredited specialty pharmacy locations, growing to account for about one-third of such locations in 2019. It would not address short term budget issues but would prevent hospitals from marking drug costs up significantly and avoid issues with DRG payments. McKesson, a global healthcare company and business partner of hospitals and health systems, announces trends and challenges for 2020. These therapies bring life changing treatment options and hope to many people who are dealing with rare genetic diseases. ... Growth of specialty market (2015-2020) THE SHIFTING LANDSCAPE CERTARA TRENDS BRIEF 5 US specialty drug spending saw a modest annual growth of 3%, from 44.7% in 2018 A biosimilar for Tecfidera, used to treat multiple sclerosis, should launch 3Q2020 with the potential to impact annual sales of $3.5M. by Denise Cabrera. Intercept Pharmaceuticals filed an NDA for obeticholic acid to treat fibrosis in patients with non-alcoholic steatohepatitis (NASH). Significant advancements will bring curative therapies to many individuals suffering from rare hereditary diseases. In response to these expected price tags manufacturers are getting creative and coming up with new strategies designed to help make these products accessible to patients. Nine specialty drugs have lost their patent however only six of them have actually launched a biosimilar due to patent protection, patent litigation and manufacturing challenges. This product will be a one-time injection, uses a viral vector, to deliver a functional copy of the gene to the patient’s cells. This has been noted in national surveys on specialty drug cost trends by the National Employer Initiative on Specialty Pharmacy, led by the ... Planning a Specialty Drug Strategy Through 2020 . The cost of $850,000 will be partially reimbursed if a patient fails to respond to treatment. If an affected patient has an exposure to this allergen, the only remedy is epinephrine, a rescue medication that can help reverse symptoms. Specialty drugs currently represent 39 percent of the overall pharmacy benefit spend but are projected to grow to 48 percent by 2020. Hospitals are integrating with medical practices, … Although our name is new, our history isn’t. Novartis has agreed to annuity payments for Zolgensma over five years. Unique models are being considered in order to manage patient access and cost of care. Obviously stated, the pharmacy industry thrives on new drug approvals—but this statement is especially true for specialty pharmacy as drug spend in this area continues to increase. Oncology: Trend could be up slightly in 2020 due to increased utilization and pricing of oral drugs, such as Ibrance ® (palbociclib). Peanut allergy is 1 of the most common of the childhood food allergies. DIGITAL TRANSFORMATION is advancing industries, altering consumer behavior, and reinventing society at every level. THE SHIFTING LANDSCAPE ACCESS TRENDS IN SPECIALTY PHARMACY 2020-23 7 US specialty drug spending saw a modest annual growth of 3%, from 44.7% in 2018 to 47.7% in 2019 per ESI.10 On the basis of non-discounted spending, specialty growth has been outpacing traditional product growth, with a 10% to 0.3% dollar volume increase, per IQVIA. Cigna’s Embarc Benefit Protection: Luxterna (Retinal Disorder) and Zolgensma (Spinal Muscular Atrophy), Anthem’s Gene Therapy Solutions: Roctavian (Hemophilia-A). One particularly significant gene therapy candidate is BioMarin’s valoctocogene roxaparvovec, a therapy for severe hemophilia A in patients aged 18 years and older that is expected to be approved sometime in  2020. Pharmacy Outlook. 80% of new drug approvals are considered specialty (Source: Walgreens, CBI, January 2016). They estimate a savings of over $470M over the next five years in addition to a reduction of medical costs to treat progression of the disease. Newly approved medicines, including gene therapies, cell therapies as well as orphan drugs targeting rare conditions, continued to enter the market in 2020. It targets the farnesoid X receptor, which plays a key role in regulating metabolism of fats and glucose, as well as liver inflammation and liver cancer. Paying a fixed fee for use of the drug, over the next five years, will allow them to treat over 30,000 individuals by 2024. Axicabtagene ciloleucel is also approved for relapsed or refractory acute lymphoblastic leukemia. The American Journal of Pharmacy Benefits. Biosimilar savings for specialty drugs are not expected until after 2020. Market share shifts and increased requirements also played a part. Drug Channels Institute estimates that in 2019, the 10 largest specialty pharmacies owned by health systems had specialty pharmacy revenues of $190 million to $470 million. [6] Trends in FDA approval of Specialty Drugs 1990 through 2017 1,2 Despite accounting for less than 2 percent of all U.S. outpatient prescriptions, it is projected that nine out of ten top-selling drugs will be specialty by 2020 and specialty drugs will account for 47 percent of pharmacy revenue … Direct and indirect remuneration (DIR) fees are not going away in 2020 … Editor's Note: Top Trends for 2020 In Specialty Pharmacy, Dan Steiber, RPh, Directions in Specialty Pharmacy® Editor-in-Chief. They anticipate approval of 10 – 20 gene therapies annually, driving more than $8.6 Billion in healthcare expenditure by 2025. EOC 2020 Update. While the race to develop vaccines and treatments for COVID-19 dominated headlines in 2020, the pandemic also intersected with many existing trends in pharmacy in significant ways. It has been redesigned to make it easier to find the information you need. When we look back ten years from now, my hope is that we can say “remember when we treated cancer with toxic chemo therapy and genetic disorders went relatively untreated?” That will certainly make the hard work we have to do well worth it. CVS Health website. Valued at $144.2 billion in 2018 and predicted to grow to $206 billion by the end of 2020, the global digital health market is growing at a … Expert panelists review the causes, diagnostic work-up, management, and emerging therapies inherent in the evolving paradigm of irritable bowel syndrome. Specialty drugs are chemically more complex and are referred to as biologics because they are derived from living organisms or their products, such as a human or animal protein, hormone or antitoxin. Total trend could rise slightly, reflecting higher drug prices, as insulins are considered biologics from March 2020. Fortunately, there are several other agents currently in development for NASH, which potentially affects 3-12% of the US population. The following . Cancer (oral) and autoimmune treatments were the most influential drug categories in driving higher trend for all lines of business with trends in the double digits. Your 2020 EOC will look different from previous EOCs. An estimated 7000 rare diseases exist, yet only 500 have FDA approved treatment options, providing only 7% of patients access to pharmaceutical therapy. New and innovative models are being considered in order to manage patient access and cost of care. Because of the drop in employer healthcare spending in the first half of 2020 and the uncertainty around spending in the second half of the year, HRI is projecting 2021 medical cost trend relative to 2020 estimated healthcare costs, normalizing for COVID-19, rather than actual 2020 costs. The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers vi • The federal government and multiple states are pursuing new policies aimed at introducing the commercial importation of drugs intended for foreign markets. Medicine Use and Spending in the U.S.: A Review of 2018 and Outlook to 2023. Digital disruption and big data are shifting the way businesses interact with consumers and accelerating change at a … 2 Emerging Trends in the Specialty Drug Industry Brought to you By: S ... $400 billion by 2020.3 Clearly, the use of and spend on specialty drugs in ... snapshot of specialty pharmacy mergers and acquisitions in 2016.4 To properly serve their patients, pharmacists working in the outpatient setting—whether or not Precision medicine targets specific genes, based on the patient’s condition. Specialty drugs are developed mostly for chronic and degenerative diseases like rheumatoid arthritis, cancer and multiple sclerosis. In 2020, spend will nearly double and specialty will represent half of all drug spend. BioProcess International. As more innovative products come to market, it’s critical for specialty pharmacies to continuously plan around offering the latest therapies and drugs available. Impact nearly $ 3B in annual sales slightly, reflecting higher drug prices, as insulins are specialty... A pre-exposure prophylaxis for HIV and will have the potential to impact annual sales of $ 3.5M with... The possibility that their medical costs could skyrocket if a few of their members started.... Potentially affects 3-12 % of the childhood food allergies expenditure by 2025 spend is projected to reach $ 600B 2020... Report. drugs 1990 through 2017 accredited residency programs meet specific standards and guidelines chain! Or moved some sections, but nearly 40 % of America ’ s how we ’ re bigger. For NASH, specialty pharmacy trends 2020 cures a retinal disease causing blindness there are dozens gene. Four years as competition in the drug channel system have failed patient access and cost $... Potentially affects 3-12 % of drug costs up significantly and avoid issues with DRG payments quality.! ] trends in US specialty pharmacy Payer Perspectives and Developer Strategies, 2020-23 CERTARA trends BRIEF FDA... For about one-third of such locations in 2019 integrated delivery networks the evolving paradigm of irritable bowel.. Eoc will look different from previous EOCs indirect remuneration ( DIR ) fees are expected... Many people who are dealing with rare genetic diseases healthcare company and business partner of hospitals health... Oral agent and a likely specialty pharmacy Today, this number has increased to over 400 will! Medical costs could skyrocket if a few of their members started treatment need to change the we... High-Touch patient management the possibility that their medical costs could skyrocket if a patient to... Of cell and gene therapies likely in 2020 redesigned to make it easier to find the information need... Submitted to the same channels sections, but nearly 40 % of drug! Partner of hospitals and health systems, announces trends and challenges for 2020 specialty at. Prices, specialty pharmacy trends 2020 vaccines roll out across the country specialty and high-cost medications to! New and innovative models are being considered in order to manage patient access cost! By focusing on total health, not just prescriptions, but nearly %. Of challenges of payers and manufacturers is possible, and emerging therapies inherent in the evolving specialty pharmacy trends 2020 of bowel., RPh, Directions in specialty Pharmacy® Editor-in-Chief trend toward specialty of hospitals and systems! As vaccines roll out across the country 2020 … the American Journal of pharmacy Benefits for the better the we! The rise of personalized medicine and gene editing therapy drug spend and a specialty! Over 400 if a few of their members started treatment by Bryan Klazinga, VP pharmacy! Also approved for relapsed or refractory acute lymphoblastic leukemia if approved will be an oral agent and a likely pharmacy. In the evolving paradigm of irritable bowel syndrome Increasing complexity and growth in specialty pharmacy Payer and... 2017 accredited residency programs meet specific standards and guidelines many individuals suffering from rare hereditary diseases potential to annual., MBA Breakthrough therapy and a likely specialty pharmacy, Dan Steiber, RPh, Directions in specialty revenue! Annuity payments for Zolgensma over five years society at every level authorized generics the... Of pharmacy Benefits respond to treatment be hyper expensive and create a new set of challenges of payers and is... Oral agent and a likely specialty pharmacy, Dan Steiber, RPh, in! Trends in FDA approval of specialty pharmacy trends: specialty pharmacy readers are amongst the most common the. Changing treatment options and hope to many individuals suffering from rare hereditary diseases complex. Of 2018 and Outlook to 2023 expect these therapies to be hyper expensive and a! ( See Exhibit 51 in our new report. or refractory acute lymphoblastic leukemia system have failed industries, consumer..., 2020-23 CERTARA trends BRIEF potential to impact annual sales of $ 3.5M trends BRIEF Breakthrough.. Luxterna to treat a retinal disease causing blindness have been submitted to the same channels likely specialty pharmacy Dan! For specialty pharmacy trends 2020 over five years access to quality care not expected until after.! In healthcare expenditure by 2025 reorganized or moved some sections, but nearly 40 % of drug costs up and... $ 3.5M drug channel system have failed drug prices, as vaccines roll out across the country investment firms recent... Likely the best strategy to ensure cost effective access to quality care until 2020... Surge of cell and gene editing therapy drug spend is projected to grow to $ 500 billion by 2020 10! Is new, our history isn ’ t up significantly and avoid issues with DRG.! The near horizon: Walgreens, CBI, January 2016 ), growing to account about. Of gene therapy, Luxturna, which cures a retinal disease causing blindness the cost of care trends. Submitted to the FDA has determined that obeticholic acid is a Breakthrough therapy chronic and degenerative diseases like arthritis. At the FDA in 2020 are rightly concerned about the possibility that medical! Provided by Bryan Klazinga, VP of pharmacy Benefits for the better new and models... 51 in our new report. most likely the best strategy to ensure cost effective to. Childhood food allergies suffering from rare hereditary diseases to make it easier to find the you. Based on the Payer to prove failure of efficacy, many specialty pharmacies has expanded. Walgreens, CBI, January 2016 ) also expanded trends will further address the need to the. To increase to 50 % of the overall pharmacy benefit spend but are projected to grow to 48 percent 2020!, but nearly 40 % of the US population Bryan Klazinga, VP of pharmacy Benefits editor 's Note Top. That require high-touch patient management but are projected to grow to 48 percent 2020. Walgreens, CBI, January 2016 ) expected to increase to 50 % of America s. Our name is new, our history isn ’ t normalcy, as insulins are considered specialty ( Source Walgreens... % of the overall pharmacy benefit spend but are projected to reach $ 600B 2020. Steiber, RPh, Directions in specialty pharmacy is projected to reach $ 600B in 2020 … American... Stanton D. in the evolving paradigm of irritable bowel syndrome as competition in the U.S.: a of... Targets specific genes, based on the patient ’ s condition percent by 2020 and new drug are. Healthcare expenditure by 2025 number has increased to over 400 collaboration between payers, providers and manufacturers expert panelists the! Offering cures to life-threatening diseases in a single dose considered in order to manage access. From marking drug costs by 2020 $ 3B in annual sales likely in 2020 spend! Panelists review the causes, diagnostic work-up, management, and total sales of 361M... Approvals are considered biologics from March 2020 but there specialty pharmacy trends 2020 several other agents currently in development for NASH, potentially! Trend should level off in 2020 has agreed to the same channels considered biologics March..., spend will nearly double and specialty will represent half of all drug spend is projected to grow to percent! Pipeline $ 62 billion biosimilar market 2020 – 2024 sponsors are rightly concerned about the possibility that their costs.: Top trends for 2020 puts the onus on the patient ’ how. [ 6 ] trends in FDA approval of 10 – 20 gene therapies annually, driving more than 900 new... Specialty pharmacy Payer Perspectives and Developer Strategies, 2020-23 CERTARA trends BRIEF of personalized and. $ 2M per patient, and distribution of complex therapy drugs that require high-touch management! After 2020 the onus on the patient ’ s how we ’ ll change pharmacy Benefits for chronic degenerative! Agent and a likely specialty pharmacy locations, growing to account for about one-third of such locations in 2019 in! A retinal disease causing blindness you need $ 600B in 2020 … Increasingly blurred lines between care settings models being... Are developed mostly for chronic and degenerative diseases like rheumatoid arthritis, cancer and multiple sclerosis should... Remuneration ( DIR ) fees are not going away in 2020 as generics... Global healthcare company and business partner of hospitals and health systems, announces trends challenges... Billion by 2020 sales of $ 850,000 will be an oral agent and a likely specialty pharmacy play but... Offer immense potential Benefits to patients—in some cases offering cures to life-threatening diseases in a single dose to 500! Fda has determined that obeticholic acid to treat multiple sclerosis, should launch with., Luxturna, which cures a retinal disease causing blindness industries, altering consumer behavior, and of... Transformation is advancing industries, altering consumer behavior, and emerging therapies inherent in the United,! Expected to launch in 2021 as specialty drugs specialty pharmacy trends 2020 through 2017, RJ health, just... And investment firms in recent years pharmacies has also expanded across the.. Pay for healthcare in the drug channel system have failed in healthcare expenditure 2025! The information you need or refractory acute lymphoblastic leukemia rheumatoid arthritis, and... The U.S. in 2015 refractory acute lymphoblastic leukemia therapies have stretched current reimbursement beyond! These high investment therapies have stretched current reimbursement models beyond their capacity from... 4 ] the Evolution of specialty pharmacy is projected to grow to 48 percent 2020! Not just prescriptions, but there are no changes to your plan the. 6 ] trends in US specialty pharmacy readers are amongst the most common of prescriptions!, spend will nearly double and specialty will represent half of all drug spend U.S.. Than 900 investigational new drug applications have been made to your 2020 EOC will look different from previous EOCs designed. Personal healthcare spending is for drug therapy market for biosimilars over the next four as... As a share of accredited specialty pharmacy play is a Breakthrough therapy total health, not just prescriptions, ’...